PGx Resources
Pharmacogenetics & the Risks ADRs
A key benefit of Pharmacogenetic Testing (PGx) is reducing the risk of Adverse Drug Reactions (ADRs). Despite rigorous testing by the U.S. Food and Drug Administration (FDA), there is still a risk that a medication can cause unintended side effects, often related to your unique DNA dictating how your body processes a medication. The FDA describes ADRs as “unwanted undesirable effects” that can “vary from minor problems like a runny nose to life-threatening events, such as a heart attack or liver damage.”
The overall risks of ADRs are significant, leading to an estimated 100,000+ deaths each year. Studies show that 98% of people carry at least one genetic variant known to cause atypical drug results.
Pharmacogenetic Testing (PGx) can identify these genetic variants so you and your physician can make the most educated and precise treatment plan and reduce the chances of a serious adverse drug reaction.
Finding and Learning about Side Effects (adverse reactions)
https://www.fda.gov/drugs/information-consumers-and-patients-drugs/finding-and-learning-about-side-effects-adverse-reactions
Preventable Adverse Drug Reactions: A Focus on Drug Interactions
https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions
Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program
https://www.mdpi.com/2075-4426/12/3/421
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
https://pubmed.ncbi.nlm.nih.gov/34948113/
Pharmacogenomics: Prescribing Precisely
https://pubmed.ncbi.nlm.nih.gov/31582008/
Pharmacogenomics for Primary Care: An Overview
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696803/
Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good
https://humgenomics.biomedcentral.com/articles/10.1186/s40246-019-0229-z
An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis
https://www.frontiersin.org/articles/10.3389/fgene.2021.698148/full
We’re committed to providing the highest level of service to our patients, healthcare providers, and business clients. If you have questions, concerns, or comments, please contact us at info@promusdiagnostics.com.